You are here

Study of Bosutinib in Japanese Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

Last updated on December 6, 2018

FOR MORE INFORMATION
Study Location
Fujita Health University Hospital
Toyoake-City, Aichi, 470-1192 Japan
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Chronic Myelogenous Leukemia
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
20 + years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

- Diagnosis of CP CML of ≤6 months (from initial diagnosis); Diagnosis of CP CML with
molecular confirmation by detection of BCR-ABL rearrangement at screening (cytogenetic
assessment for Ph is not required for enrollment; however, patients with known Ph- CML
prior to registration are not eligible for this study)

- Age ≥20 years

- Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1

- Adequate Liver and Renal Function

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

- Any prior medical treatment for CML, including TKIs, with the exception of hydroxyurea
treatment, which is permitted for up to 6 months prior to registration

- Any past or current CNS involvement, including leptomeningeal leukemia

- Extramedullary disease only

- Major surgery or radiotherapy within 14 days prior to registration

- History of clinically significant or uncontrolled cardiac disease

- Patients with active, uncontrolled bacterial, fungal, or viral infection

- Recent or ongoing clinically significant GI disorder

- History of another malignancy within 5 years prior to registration

- Uncontrolled hypomagnesemia or uncorrected hypokalemia due to potential effects on the
QT interval

- Known prior or suspected severe hypersensitivity to study drugs or any component in
their formulations

- Participation in other studies involving investigational drug(s) within 30 days or 5
half-lives of investigational product, whichever is longer, prior to registration
and/or during study participation

- Other severe acute or chronic medical or psychiatric condition, including recent or
active suicidal ideation or behavior, or laboratory abnormality that may increase the
risk associated with study participation or interfere with the interpretation of study
results

- Investigational site staff members directly involved in the conduct of the study and
their family members, or Pfizer employees, including their family members, directly
involved in the conduct of the study

NCT03128411
Pfizer
Active, not recruiting
Study of Bosutinib in Japanese Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your zip code, city, or country to find studies near you.
Study of Bosutinib in Japanese Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
A Phase 2, Open-label, Single-arm Study To Evaluate Efficacy And Safety Of Bosutinib Monotherapy In Japanese Adult Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia
Phase 2, single-arm, open-label trial. Patients will receive bosutinib for the duration of the study.
The study will be open for enrollment until the planned number of approximately 60 Philadelphia Chromosome Positive (Ph+) patients have been registered. All patients will be treated and/or followed for up to approximately 3 years (144 weeks) after registration of the last patient or until study termination. Patients who discontinue study therapy early due to disease progression or intolerance to study medication will continue to be followed yearly for survival for up to approximately 3 years (144 weeks) after registration of the last patient or until study termination.
Interventional
Phase 2
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Leukemia, Chronic Myelogenous
Drug: Bosutinib
All patinets will receive bosutinib at a starting dose of 400 mg QD.
Experimental: Bosutinib
Bosutinib monotherapy; All patients will receive bosutinib at a starting dose of 400 mg QD. The dose of bosutinib may be escalated (up to a maximum of 600 mg QD) for unsatisfactory response or reduced for toxicity.
Intervention: Drug: Bosutinib
Not Provided


*   Includes publications given by the data provider as well as publications
identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
60
November 30, 2020
May 31, 2019   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Diagnosis of CP CML of ?6 months (from initial diagnosis); Diagnosis of CP CML with molecular confirmation by detection of BCR-ABL rearrangement at screening (cytogenetic assessment for Ph is not required for enrollment; however, patients with known Ph- CML prior to registration are not eligible for this study)
  • Age ?20 years
  • Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1
  • Adequate Liver and Renal Function

Exclusion Criteria:

  • Any prior medical treatment for CML, including TKIs, with the exception of hydroxyurea treatment, which is permitted for up to 6 months prior to registration
  • Any past or current CNS involvement, including leptomeningeal leukemia
  • Extramedullary disease only
  • Major surgery or radiotherapy within 14 days prior to registration
  • History of clinically significant or uncontrolled cardiac disease
  • Patients with active, uncontrolled bacterial, fungal, or viral infection
  • Recent or ongoing clinically significant GI disorder
  • History of another malignancy within 5 years prior to registration
  • Uncontrolled hypomagnesemia or uncorrected hypokalemia due to potential effects on the QT interval
  • Known prior or suspected severe hypersensitivity to study drugs or any component in their formulations
  • Participation in other studies involving investigational drug(s) within 30 days or 5 half-lives of investigational product, whichever is longer, prior to registration and/or during study participation
  • Other severe acute or chronic medical or psychiatric condition, including recent or active suicidal ideation or behavior, or laboratory abnormality that may increase the risk associated with study participation or interfere with the interpretation of study results
  • Investigational site staff members directly involved in the conduct of the study and their family members, or Pfizer employees, including their family members, directly involved in the conduct of the study
Sexes Eligible for Study: All
20 Years and older   (Adult, Senior)
No

Contact: Pfizer CT.gov Call Center 1-800-718-1021 Clinical[email protected]
Japan
 
 
NCT03128411
B1871048
No
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Plan to Share IPD: Yes
Plan Description: Information relating to our policy on data sharing and the process for requesting data can be found at the following link: http://www.pfizer.com/research/clinical_trials/trial_data_and_results/da...
URL: http://
Pfizer
Pfizer
Not Provided
Study Director: Pfizer CT.gov Call Center Pfizer
Pfizer
December 2017

ICMJE     Data element required by the

International Committee of Medical Journal Editors
and the
World Health Organization ICTRP

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting thte study website. To get updates and notications about this trail, sign up using the form below.

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]



Call Now